A case of successful treatment of complete atrioventricular block complicated by sudden arrhythmic death in an elderly patient with post COVID-19 thrombocytopenia
Open Access
- 22 January 2022
- journal article
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 11 (2), 103-120
- https://doi.org/10.21518/2307-1109-2021-11-2-103-120
Abstract
As established today by a number of studies, transferred COVID-19 (even mild) is associated with a high risk of delayed heart damage. Although human coronaviruses are a minor cause of all cases of viral myocarditis, they have been associated with myocarditis in patients of all age groups. Post-COVID-19 myocarditis can be manifested by heart failure, heart rhythm and conduction disorders. A case report of 14-day hospitalization of an 89 y.o. man for a life-threatening myocardial conduction disorder – complete AV block – on the background of a permanent form of Arial fibrillation, accompanied by clinical death of the patient, coagulopathy, nosocomial pneumonia, heart failure and impaired consciousness. During the treatment, which included cardiopulmonary resuscitation, the use of temporary and then permanent pacemaker, antibiotics, levocarnitine, Fondaparinux, blood clot transfusions for profound thrombocytopenia, led to the restoration of heart rhythm and conduction, reduction of heart failure, cure of nosocomial pneumonia and restoration of exercise tolerance. Post- COVID-19 complications are currently still weakly understood and poorly predicted, but their treatment according to the general rules gives positive results. In patients with heparin-induced thrombocytopenia, as in patients with initial thrombocytopenia (including after COVID-19 conditions), it is advisable to use the drug Fondaparinux, which has proven itself in the prevention and treatment of arterial and venous thromboembolism. In the treatment of posthypoxic complications, it is appropriate to use Levocarnitine to correct post-ischemic changes in the myocardium and brain.Keywords
This publication has 23 references indexed in Scilit:
- Nonheparin Anticoagulants for Heparin-Induced ThrombocytopeniaThe New England Journal of Medicine, 2013
- Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second editionBritish Journal of Haematology, 2012
- How I treat heparin-induced thrombocytopeniaBlood, 2012
- Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Thrombocytopenia in the Intensive Care Unit PatientHematology, 2010
- Heparin-Induced ThrombocytopeniaSeminars in Cardiothoracic and Vascular Anesthesia, 2010
- Fondaparinux for the Treatment of Acute Heparin-Induced Thrombocytopenia: A Single-Center ExperienceClinical and Applied Thrombosis/hemostasis, 2009
- Immune heparin‐induced thrombocytopenia resulting from preceding exposure to heparin catheter flushesAmerican Journal of Hematology, 2006
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparinBlood, 2005